Harmony Biosciences (HRMY) Says Goodbye To Its CFO And Names An Interim Finance Chief

July 24, 2026 - 01:08

Harmony Biosciences Holdings (NasdaqGM:HRMY) announced the resignation of Chief Financial Officer Glenn Reicin, marking a shift in its top financial leadership. The company has appointed Stephen Mollichella as interim Principal Financial Officer, effective immediately upon Reicin's departure.

The change impacts key areas of the company's operations, including financial reporting, capital allocation, and investor communications. As a biopharmaceutical firm focused on developing therapies for rare neurological conditions, Harmony Biosciences relies heavily on stable financial guidance to support clinical trials and regulatory processes.

Mollichella steps into the role during a period when the company is navigating the costs and timelines associated with bringing new treatments to market. The appointment of an interim finance chief suggests the company will conduct a search for a permanent replacement while maintaining continuity in its financial operations.

Harmony Biosciences has not provided further details on the reasons for Reicin's departure or the timeline for naming a permanent CFO. The company continues to advance its pipeline of therapies aimed at underserved patient populations with neurological disorders.